UPDATE: Wedbush Downgrades Ironwood Pharmaceuticals to Underperform on Higher Lizness Costs

In a report published Wednesday, Wedbush analyst Gregory R. Wade downgraded the rating on Ironwood Pharmaceuticals (NASDAQ: IRWD ) from Neutral to Underperform, and slightly lowered the price target from $13.00 to $12.00. In the report, Wade noted, “IRWD reported a cash burn of $93M in the quarter, ahead of